Skip to main content
SpringerLink
Log in

Sedation and Analgesia in Neurointensive Care

  • Chapter
  • First Online:
Textbook of Neurointensive Care

Abstract

In the neurointensive care setting, specific considerations of sedation are required; sedation may act as a therapeutic agent itself, when causing a reduction in cerebral metabolic rate of oxygen, cerebral blood flow, and intracranial pressure and in the incidence of seizures. However, the physician must be aware of the effects of every sedative agent on cerebral physiology, in order to obtain beneficial effects and avoid side effects. In this chapter, the effects of sedative agents on cerebral physiology are described in order to provide knowledge for an adequate sedative strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kress JP, Pohlman AS, O’Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342:1471–7.

    Article  PubMed  CAS  Google Scholar 

  2. Hogarth DK, Hall J. Management of sedation in mechanically ventilated patients. Curr Opin Crit Care. 2004;10(1):40–6.

    Article  PubMed  Google Scholar 

  3. Hukkelhoven CW, Steyerberg EW, Farace E, et al. Regional differences in patient characteristics, case management, and outcomes in traumatic brain injury: experience from the tirilazad trials. J Neurosurg. 2002;97:549–57.

    Article  PubMed  Google Scholar 

  4. Bertolini G, Melotti R, Romano P, et al. Use of sedative and analgesic drugs in the first week of ICU stay. A pharmaco-epidemiological perspective. Minerva Anestesiol. 2001;67:97–105.

    PubMed  CAS  Google Scholar 

  5. Soliman HM, Melot C, Vincent JL. Sedative and analgesic practice in the intensive care unit: the results of a European survey. Br J Anaesth. 2001;87:186–92.

    Article  PubMed  CAS  Google Scholar 

  6. Rhoney DH, Parker D Jr. Use of sedative and analgesic agents in neurotrauma patients: effects on cerebral physiology. Neurol Res. 2001; 23:237–259.

    Google Scholar 

  7. Jacobi J, Fraser GL, Coursin DB, et al. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30:119–41.

    Article  PubMed  Google Scholar 

  8. Cohen IL, Abraham E, Dasta JF, et al. Management of the agitated intensive care unit patient. Crit Care Med. 2002;30(suppl):S116–7.

    Google Scholar 

  9. Blanchard AR. Sedation and analgesia in intensive care. Medications attenuate stress response in critical illness. Postgrad Med. 2002;111:59–60, 63–4, 67–70.

    PubMed  Google Scholar 

  10. Gemma M, Tommasino C, Cerri M, et al. Intracranial effects of endotracheal suctioning in the acute phase of head injury. J Neurosurg Anesthesiol. 2002;14:50–4.

    Article  PubMed  Google Scholar 

  11. Hurford WE. Sedation and paralysis during mechanical ventilation. Respir Care. 2002;47:334–46.

    PubMed  Google Scholar 

  12. Gehlbach BK, Kress JP. Sedation in the intensive care unit. Curr Opin Crit Care. 2002;8:290–8.

    Article  PubMed  Google Scholar 

  13. Kress JP, Pohlman AS, Hall JB. Sedation and analgesia in the intensive care unit. Am J Respir Crit Care Med. 2002;166:1024–8.

    Article  PubMed  Google Scholar 

  14. Ostermann ME, Keenan SP, Seiferling RA, et al. Sedation in the intensive care unit: a systematic review. JAMA. 2000;283:1451–9.

    Article  PubMed  CAS  Google Scholar 

  15. Mirski MA, Muffelman B, Ulatowski JA, et al. Sedation for the critically ill neurologic patient. Crit Care Med. 1995;23:2038–53.

    Article  PubMed  CAS  Google Scholar 

  16. Prielipp RC, Coursin DB. Sedative and neuromuscular blocking drug use in critically ill patients with head injuries. New Horiz. 1995;3:458–68.

    Google Scholar 

  17. Kraus JJ, Metzler MD, Coplin WM. Critical care issues in stroke and subarachnoid hemorrhage. Neurol Res. 2002;24 suppl 1:S47–57.

    Article  PubMed  Google Scholar 

  18. Oertel M, Kelly DF, Lee JH, et al. Metabolic suppressive therapy as a treatment for intracranial hypertension—why it works and when it fails. Acta Neurochir Suppl. 2002;81:69–70.

    PubMed  CAS  Google Scholar 

  19. Robertson CS, Cormio M. Cerebral metabolic management. New Horiz. 1995;3:410–22.

    PubMed  CAS  Google Scholar 

  20. Clausen T, Bullock R. Medical treatment and neuroprotection in traumatic brain injury. Curr Pharm Des. 2001;7:1517–32.

    Article  PubMed  CAS  Google Scholar 

  21. Grasshoff C, Gillessen T. The effect of propofol on increased superoxide concentration in cultured rat cerebrocortical neurons after stimulation of N-methyl-d-aspartate receptors. Anesth Analg. 2002;95:920–2.

    PubMed  CAS  Google Scholar 

  22. Starbuck VN, Kay GG, Platenberg RC, et al. Functional magnetic resonance imaging reflects changes in brain functioning with sedation. Hum Psychopharmacol. 2000;15:613–8.

    Article  PubMed  Google Scholar 

  23. Oshima T, Karasawa F, Satoh T. Effects of propofol on cerebral blood flow and the metabolic rate of oxygen in humans. Acta Anaesthesiol Scand. 2002;46(7):831–5.

    Article  PubMed  CAS  Google Scholar 

  24. Engelhard K, Werner C. Inhalational or intravenous anesthetics for craniotomies? Pro inhalational. Curr Opin Anaesthesiol. 2006;19:504–8.

    Article  PubMed  Google Scholar 

  25. Trescot AM, Datta S, Lee M, et al. Opioid pharmacology. Pain Physician. 2008;11(2 Suppl):S133–53.

    PubMed  Google Scholar 

  26. Armstrong PJ, Bersten A. Normeperidine toxicity. Anesth Analg. 1986;65(5):536–8.

    Article  PubMed  CAS  Google Scholar 

  27. Barr J, Donner A. Optimal intravenous dosing strategies for sedatives and analgesics in the intensive care unit. Crit Care Clin. 1995;11(4):827–47.

    PubMed  CAS  Google Scholar 

  28. Angelini G, Ketzler JT, Coursin DB. Use of propofol and other nonbenzodiazepine sedatives in the intensive care unit. Crit Care Clin. 2001;17:863–80.

    Article  PubMed  CAS  Google Scholar 

  29. Magarey JM. Propofol or midazolam – which is best for the sedation of adult ventilated patients in intensive care units? A systematic review. Aust Crit Care. 2001;14:147–54.

    Article  PubMed  CAS  Google Scholar 

  30. Walder B, Elia N, Henzi I, et al. A lack of evidence of superiority of propofol versus midazolam for sedation in mechanically ventilated critically ill patients: a qualitative and quantitative systematic review. Anesth Analg. 2001;92:975–83.

    Article  PubMed  CAS  Google Scholar 

  31. Weinbroum AA, Halpern P, Rudick V, et al. Midazolam versus propofol for long-term sedation in the ICU: a randomized prospective comparison. Intensive Care Med. 1997;23:1258–63.

    Article  PubMed  CAS  Google Scholar 

  32. Power KN, Flaatten H, Gilhus NE, Engelsen BA. Propofol treatment in adult refractory status epilepticus. Mortality risk and outcome. Epilepsy Res. 2011;94(1–2):53–60.

    Article  PubMed  CAS  Google Scholar 

  33. Meierkord H, Boon P, Engelsen B, Göcke K, Shorvon S, Tinuper P, Holtkamp M, European Federation of Neurological Societies. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.

    Article  PubMed  CAS  Google Scholar 

  34. Marik PE, Varon J. The management of status epilepticus. Chest. 2004;126(2):582–91.

    Article  PubMed  Google Scholar 

  35. Rosow C. Remifentanil: a unique opioid analgesic. Anesthesiology. 1993;79:875–6.

    PubMed  CAS  Google Scholar 

  36. Pitsiu M, Wilmer A, Bodenham A, et al. Pharmacokinetics of remifentanil and its major metabolite, remifentanil acid, in ICU patients with renal impairment. Br J Anaesth. 2004;92:493–503.

    Article  PubMed  CAS  Google Scholar 

  37. Dumont L, Picard V, Marti RA, et al. Use of remifentanil in a patient with chronic hepatic failure. Br J Anaesth. 1998;81:265–7.

    Article  PubMed  CAS  Google Scholar 

  38. Peeters MY, Bras LJ, DeJongh J, et al. Disease severity is a major determinant for the pharmacodynamics of propofol in critically ill patients. Clin Pharmacol Ther. 2008;83(3):443–51.

    Article  PubMed  CAS  Google Scholar 

  39. Bladin CF, Alexandrov AV, Bellavance A, et al. Seizure after stroke: a prospective multicenter study. Arch Neurol. 2000;57:1617–22.

    Article  PubMed  CAS  Google Scholar 

  40. Reith J, Jorgensen HS, Raaschou HO, et al. Seizure in acute stroke: predictors and prognostic significance. The Copenhagen Stroke Study. Stroke. 1997;28:1585–9.

    Article  PubMed  CAS  Google Scholar 

  41. Vespa PM, Nuwer MR, Nenov V, et al. Increased incidence and impact of nonconvulsive and convulsive seizures after traumatic brain injury as detected by continuous electroencephalographic monitoring. J Neurosurg. 1999;91:750–60.

    Article  PubMed  CAS  Google Scholar 

  42. Hanley DF, Pozo M. Treatment of status epilepticus with midazolam in the critical care setting. Int J Clin Pract. 2000;54:30–5.

    PubMed  CAS  Google Scholar 

  43. Walder B, Tramer MR, Seeck M. Seizure-like phenomena and propofol: a systematic review. Neurology. 2002;58:1327–32.

    Article  PubMed  Google Scholar 

  44. Barr J, Egan TD, Sandoval NF, et al. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. Anesthesiology. 2001;95(2):324–33.

    Article  PubMed  CAS  Google Scholar 

  45. Carson SS, Kress JP, Rodgers JE, et al. A randomized trial of intermittent lorazepam versus propofol with daily interruption in mechanically ventilated patients. Crit Care Med. 2006;34(5):1326–32.

    Article  PubMed  CAS  Google Scholar 

  46. Mehta S, Burry L, Fischer S, et al. Canadian survey of the use of sedatives, analgesics, and neuromuscular blocking agents in critically ill patients. Crit Care Med. 2006;34(2):374–80.

    Article  PubMed  Google Scholar 

  47. Somogyi AA, Barratt DT, Coller JK. Pharmacogenetics of opioids. Clin Pharmacol Ther. 2007;81(3):429–44.

    Article  PubMed  CAS  Google Scholar 

  48. Egan TD, Lemmens HJ, Fiset P, et al. The pharmacokinetics of the new short- acting opioid remifentanil (GI87084B) in healthy adult male volunteers. Anesthesiology. 1993;79:881–92.

    Article  PubMed  CAS  Google Scholar 

  49. Delvaux B, Ryckwaert Y, Van Boven M, et al. Remifentanil in the intensive care unit: tolerance and acute withdrawal syndrome after prolonged sedation. Anesthesiology. 2005;102:1281–2.

    Article  PubMed  Google Scholar 

  50. Karabinis A, Mandragos K, Stergiopoulos S, et al. Safety and efficacy of analgesia-based sedation with remifentanil versus standard hypnotic-based regimens in intensive care unit patients with brain injuries: a randomised, controlled trial [ISRCTN50308308]. Crit Care. 2004;8:R268–80.

    Article  PubMed  Google Scholar 

  51. Engelhard K, Reeker W, Kochs E, et al. Effect of remifentanil on intracranial pres- sure and cerebral blood flow velocity in patients with head trauma. Acta Anaesthesiol Scand. 2004;48:396–9.

    Article  PubMed  CAS  Google Scholar 

  52. Charney DS, Mihic SJ, Harris RA. Hypnotics and sedatives. In: Hardman JG, Limbird LE, editors. Goodman and Gilman’s the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill; 2001. p. 399–427.

    Google Scholar 

  53. Shafer A. Complications of sedation with midazolam in the intensive care unit and a comparison with other sedative regimens. Crit Care Med. 1998;26:947–56.

    Article  PubMed  CAS  Google Scholar 

  54. Hanaoka K, Namiki A, Dohi S, et al. A dose-ranging study of midazolam for postoperative sedation of patients: a randomized, double-blind, placebo-controlled trial. Crit Care Med. 2002;30:1256–60.

    Article  PubMed  CAS  Google Scholar 

  55. Shelly MP, Mendel L, Park GR. Failure of critically ill patients to metabolise midazolam. Anaesthesia. 1987;42:619–26.

    Article  PubMed  CAS  Google Scholar 

  56. McKenzie CA, McKinnon W, Naughton DP, et al. Differentiating midazolam over sedation from neurological damage in the intensive care unit. Crit Care. 2005;9(1):R32–6.

    Article  PubMed  Google Scholar 

  57. Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway Jr SA, Murray MJ, Peruzzi WT, Lumb PD, Task Force of the American College of Critical Care Medicine (ACCM) of the Society of Critical Care Medicine (SCCM), American Society of Health-System Pharmacists (ASHP), American College of Chest Physicians. Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30(1):119–41. No abstract available. Erratum in: Crit Care Med 2002 Mar;30(3):726.

    Article  PubMed  Google Scholar 

  58. Barr J, Zomorodi K, Bertaccini EJ, et al. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. Anesthesiology. 2001;95(2):286–98.

    Article  PubMed  CAS  Google Scholar 

  59. Fukasawa T, Suzuki A, Otani K. Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines. J Clin Pharm Ther. 2007;32(4):333–41.

    Article  PubMed  CAS  Google Scholar 

  60. Yahwak JA, Riker RR, Fraser GL, et al. Determination of a lorazepam dose threshold for using the osmol gap to monitor for propylene glycol toxicity. Pharmacotherapy. 2008;28(8):984–91.

    Article  PubMed  CAS  Google Scholar 

  61. Barnes BJ, Gerst C, Smith JR, et al. Osmol gap as a surrogate marker for serum propylene glycol concentrations in patients receiving lorazepam for sedation. Pharmacotherapy. 2006;26(1):23–33.

    Article  PubMed  CAS  Google Scholar 

  62. Tweed WA, Minuck MS, Mymin D. Circulatory responses to ketamine anesthesia. Anesthesiology. 1972;37:613–9.

    Article  PubMed  CAS  Google Scholar 

  63. Gardner AE, Dannemiller FJ, Dean D. Intracranial cerebrospinal fluid pressure in man during ketamine anesthesia. Anesth Analg. 1972;51:741–5.

    Article  PubMed  CAS  Google Scholar 

  64. Takeshita H, Okuda Y, Sari A. The effects of ketamine on cerebral circulation and metabolism in man. Anesthesiology. 1972;36:69–75.

    Article  PubMed  CAS  Google Scholar 

  65. Albanèse J, Arnaud S, Rey M, et al. Ketamine decreases intracranial pressure and electroencephalographic activity in traumatic brain injury patients during propofol sedation. Anesthesiology. 1997;87(6):1328–34.

    Article  PubMed  Google Scholar 

  66. Shapira Y, Lam AM, Eng CC, et al. Therapeutic time window and dose response of the beneficial effects of ketamine in experimental head injury. Stroke. 1994;25:1637–43.

    Article  PubMed  CAS  Google Scholar 

  67. Bourgoin A, Albanèse J, Wereszczynski N, Charbit M, Vialet R, Martin C. Safety of sedation with ketamine in severe head injury patients: comparison with sufentanil. Crit Care Med. 2003;31:711–7.

    Article  PubMed  CAS  Google Scholar 

  68. Coursin DB, Coursin DB, Maccioli GA. Dexmedetomidine. Curr Opin Crit Care. 2001;7:221–6.

    Article  PubMed  CAS  Google Scholar 

  69. Drummond G. Dexmedetomidine may be effective, but is it safe? Br J Anaesth. 2002;88:454–5.

    Article  PubMed  Google Scholar 

  70. Maze M, Scarfini C, Cavaliere F. New agents for sedation in the intensive care unit. Crit Care Clin. 2001;17:881–97.

    Article  PubMed  CAS  Google Scholar 

  71. Shelly MP. Dexmedetomidine: a real innovation or more of the same? Br J Anaesth. 2001;87:677–8.

    Article  PubMed  CAS  Google Scholar 

  72. De Wolf AM, Fragen RJ, Avram MJ, Fitzgerald PC, Rahimi-Danesh F. The pharmacokinetics of dexmedetomidine in volunteers with severe renal impairment. Anesth Analg. 2001;93:1205–9.

    Article  PubMed  Google Scholar 

  73. Belleville JP. Effects of intravenous dexmedetomidine in humans: part I: sedation, ventilation, and metabolic rate. Anesthesiology. 1992;77:1125–33.

    Article  PubMed  CAS  Google Scholar 

  74. Bloor BC, Ward DS, Belleville JP, et al. Effects of intravenous dexmedetomidine in humans: part II: hemodynamic changes. Anesthesiology. 1992;77:1134–42.

    Article  PubMed  CAS  Google Scholar 

  75. Talke P, Richardson CA, Scheinin M, et al. Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine. Anesth Analg. 1997;85:1136–42.

    PubMed  CAS  Google Scholar 

  76. Triltsch AE, Welte M, von Homeyer P, et al. Bispectral index–guided sedation with dexmedetomidine in intensive care: a prospective, randomized, double blind, placebo-controlled phase II study. Crit Care Med. 2002;30:1007–14.

    Article  PubMed  CAS  Google Scholar 

  77. Venn RM, Bryant A, Hall GM, et al. Effects of dexmedetomidine on adrenocortical function, and the cardiovascular, endocrine and inflammatory responses in postoperative patients needing sedation in the intensive care unit. Br J Anaesth. 2001;86:650–6.

    Article  PubMed  CAS  Google Scholar 

  78. Ebert TJ, Hall JE, Barney JA, et al. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology. 2000;93:382–94.

    Article  PubMed  CAS  Google Scholar 

  79. Bekker A, Sturaitis MK. Dexmedetomidine for neurological surgery. Neurosurgery. 2005;57(1 Suppl):1–10.

    Article  PubMed  Google Scholar 

  80. Stump DA, James RL, Bennett J. Dexmedetomidine-induced sedation in volunteers decreases regional and global cerebral blood flow. Anesth Analg. 2002;95:1052–9.

    PubMed  Google Scholar 

  81. Drummond JC, Dao AV, Roth DM, et al. Effect of dexmedetomidine on cerebral blood flow velocity, cerebral metabolic rate, and carbon dioxide response in normal humans. Anesthesiology. 2008;108:225–32.

    Article  PubMed  CAS  Google Scholar 

  82. Coull JT, Jones ME, Egan TD, et al. Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage. 2004;22:315–22.

    Article  PubMed  Google Scholar 

  83. Doufas AG, Lin CM, Suleman MI, et al. Dexmedetomidine and meperidine additively reduce the shivering threshold in humans. Stroke. 2003;34:1218–23.

    Article  PubMed  CAS  Google Scholar 

  84. Dahmani S, Rouelle D, Gressens P, et al. Effects of dexmedetomidine on hippocampal focal adhesion kinase tyrosine phosphorylation in physiologic and ischemic conditions. Anesthesiology. 2005;103:969–77.

    Article  PubMed  CAS  Google Scholar 

  85. Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology. 2003;98:575–7.

    Article  PubMed  Google Scholar 

  86. Farag E, Chahlavi A, Argalious M, et al. Using dexmedetomidine to manage patients with cocaine and opioid withdrawal, who are undergoing cerebral angioplasty for cerebral vasospasm. Anesth Analg. 2006;103:1618–20.

    Article  PubMed  Google Scholar 

  87. Bratton SL, Chestnut RM, Ghajar J, et al. Guidelines for the management of severe traumatic brain injury XI. Anesthetics, analgesics, and sedatives. J Neurotrauma. 2007;24(1 Suppl):S71–6; Erratum in: J Neurotrauma. 2008;25(3):276–8.

    Article  Google Scholar 

  88. Meierkord H, Boon P, Engelsen B, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.

    Article  PubMed  CAS  Google Scholar 

  89. Kelly DF, Goodale DB, Williams J, et al. Propofol in the treatment of moderate and severe head injury: a randomized, prospective, double-blinded pilot trial. J Neurosurg. 1999;90:1042–52.

    Article  PubMed  CAS  Google Scholar 

  90. Cannon ML, Glazier SS, Bauman LA. Metabolic acidosis, rhabdomyolysis, and cardiovascular collapse after prolonged propofol infusion. J Neurosurg. 2001;95:1053–6.

    Article  PubMed  CAS  Google Scholar 

  91. Kelly DF. Propofol-infusion syndrome. J Neurosurg. 2001;95:925–6.

    Article  PubMed  CAS  Google Scholar 

  92. Laham J. Propofol: risk vs. benefit. Clin Pediatr (Phila). 2002;41:5–7.

    Article  Google Scholar 

  93. DeJonge B, Cook D, Appere-De-Vecchi C, et al. Using and understanding sedation scoring systems: a systematic review. Intensive Care Med. 2000;26:275–85.

    Article  Google Scholar 

  94. Brook AD, Ahrens TS, Schaiff R, et al. Effect of a nursing- implemented sedation protocol on the duration of mechanical ventilation. Crit Care Med. 1999;27(12):2609–15.

    Article  PubMed  CAS  Google Scholar 

  95. Riess ML, Graefe UA, Goeters C, et al. Sedation assessment in critically ill patients with bispectral index. Eur J Anesthesiol. 2002;19:18–22.

    CAS  Google Scholar 

  96. Klopman MA, Sebel PS. Cost-effectiveness of bispectral index monitoring. Curr Opin Anaesthesiol. 2011;24:177–81.

    Article  PubMed  Google Scholar 

  97. Sanchez-Izquierdo Riera JA, Caballero-Cubedo RE, Perez-Vela JL, et al. Propofol versus midazolam: safety and efficacy for sedating the severe trauma patient. Anesth Analg. 1998;86:1219–24.

    PubMed  CAS  Google Scholar 

  98. Olson DM, Thoyre SM, Peterson ED, Graffagnino C. A randomized evaluation of bispectral index-augmented sedation assessment in neurological patients. Neurocrit Care. 2009;11(1):20–7.

    Article  PubMed  Google Scholar 

  99. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington, D.C.: American Psychiatric Association; 2000.

    Google Scholar 

  100. Dyer CB, Ashton CM, Teasdale TA. Postoperative delirium: a review of 80 primary data collection studies. Arch Intern Med. 1995;155:461–5.

    Article  PubMed  CAS  Google Scholar 

  101. Dubois MJ, Bergeron N, Dumont M, et al. Delirium in an intensive care unit: a study of risk factors. Intensive Care Med. 2001;27:1297–304.

    Article  PubMed  CAS  Google Scholar 

  102. Marcantonio E, Juarez G, Goldman L, et al. The relationship of postoperative delirium with psychoactive medications. J Am Med Assoc. 1994;272:1518.

    Article  CAS  Google Scholar 

  103. Pandharipande P, Shintani A, Peterson J, et al. Lorazepam is an independent risk factor for transitioning to delirium in intensive care unit patients. Anesthesiology. 2006;104:21–6.

    Article  PubMed  CAS  Google Scholar 

  104. American Psychiatric Association. Practice guidelines for the treatment of patients with delirium. Am J Psychiatry. 1999;156(5 suppl):1–20.

    Google Scholar 

  105. Pandharipande P, Cotton B, Shintani A, et al. Prevalence and risk factors for development of delirium in surgical and trauma intensive care unit patients. J Trauma. 2008;65:34–41.

    Article  PubMed  Google Scholar 

  106. Lat I, McMillian W, Taylor S, et al. The impact of delirium on clinical outcomes in mechanically ventilated surgical and trauma patients. Crit Care Med. 2009;37:1898–905.

    Article  PubMed  Google Scholar 

  107. Agarwal V, O’Neill P, Cotton B, et al. Prevalence and risk factors for development of delirium in burn intensive care unit patients. J Burn Care Res. 2010;31:706–15.

    Article  PubMed  Google Scholar 

  108. Morandi A, Brummel NE, Ely EW. Sedation, delirium and mechanical ventilation: the “ABCDE” approach. Curr Opin Crit Care. 2011;17(1):43–9.

    Article  PubMed  Google Scholar 

  109. Skoglund K, Enblad P, Marklund N. Effects of the neurological wake-up test on intracranial pressure and cerebral perfusion pressure in brain-injured patients. Neurocrit Care. 2009;11(2):135–42.

    Article  PubMed  Google Scholar 

  110. Citerio G, Cormio M. Sedation in neurointensive care: advances in understanding and practice. Curr Opin Crit Care. 2003;9(2):120–6.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuro-Anesthesia and Neuro-Intensive Care Unit, Department of Anesthesia and Critical Care, Ospedale San Gerardo, Via Pergolesi 33, Monza, 20052, Italy

    Federico A. Villa MD & Giuseppe Citerio MD

Authors
  1. Federico A. Villa MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Citerio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Citerio MD .

Editor information

Editors and Affiliations

  1. Pulmonary and Critical Care Medicine, Geisinger Health System, Danville, Pennsylvania, USA

    A Joseph Layon

  2. Departments of Anesthesiology & Surgery, University of Florida College of Medicine, Gainesville, Florida, USA

    Andrea Gabrielli

  3. Department of Neurosurgery, University of Florida, Gainesville, Florida, USA

    William A. Friedman

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Villa, F.A., Citerio, G. (2013). Sedation and Analgesia in Neurointensive Care. In: Layon, A., Gabrielli, A., Friedman, W. (eds) Textbook of Neurointensive Care. Springer, London. https://doi.org/10.1007/978-1-4471-5226-2_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-5226-2_14

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-5225-5

  • Online ISBN: 978-1-4471-5226-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation